CytomX Therapeutics (CTMX) Net Income towards Common Stockholders (2014 - 2026)

CytomX Therapeutics' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$18.2 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 177.57% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.3 million (down 232.94% YoY) and the FY2025 annual result came in at -$20.4 million, down 163.92% from the prior year.
• Net Income towards Common Stockholders was -$18.2 million for Q1 2026 at CytomX Therapeutics, up from -$22.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $23.5 million in Q1 2025 and bottomed at -$32.0 million in Q1 2022.
• A 5-year average of -$5.9 million and a median of -$3.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 2155.2% in 2024, while the deepest fall reached 501.1% in 2024.
• CytomX Therapeutics' Net Income towards Common Stockholders stood at -$8.8 million in 2022, then surged by 109.54% to $837000.0 in 2023, then soared by 2155.2% to $18.9 million in 2024, then sank by 220.12% to -$22.7 million in 2025, then gained by 19.52% to -$18.2 million in 2026.
• Business Quant data shows CTMX's Net Income towards Common Stockholders at -$18.2 million in Q1 2026, -$22.7 million in Q4 2025, and -$14.2 million in Q3 2025.